查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1611025

In Silico 临床试验市场规模、份额、趋势分析报告：按行业、治疗领域、阶段、地区和细分市场预测，2025-2030 年

In Silico Clinical Trials Market Size, Share & Trends Analysis Report By Industry, By Therapeutic Area, By Phase, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

电脑模拟临床试验市场成长与趋势

Grand View Research, Inc.的最新报告显示，到2030年，全球In Silico临床试验市场规模预计将达到55.9亿美元。预计2025年至2030年该市场将以7.74%的复合年增长率成长。传统的临床试验需要大量资金来进行研究。此外，大量药品和医疗设备因缺乏安全性和有效性而在临床试验中失败，对临床试验申办者造成巨大损失。这些因素推动了对电脑临床试验的需求，以了解药物和医疗设备在人体中的行为。 In Silico 临床试验使用模拟技术来了解药物和医疗设备的有效性和安全性。

这减少了副作用的可能性并提高了研究的安全性和有效性。市场参与企业正在大力投资，为人们带来新的治疗方法。例如，2021 年 6 月，In Silico Medicine 筹集了 2.55 亿美元资金，用于透过 In Silico 研究加强药物发现的研究和开发。疫情期间，由于临床研究设施暂时关闭，并且透过 In Silico 研究模型进行了多项针对 COVID-19 的疫苗和治疗方法的研究，因此对 In Silico 临床试验的需求也有所改善。这些措施可能会对市场成长产生正面影响。

电脑模拟临床试验市场报告亮点

  • 2024 年，医疗设备领域将主导市场，因为大多数 In Silico 临床试验都是在全球医疗设备上进行的。
  • 2024年，二期业务占据最大的市场收益占有率。
  • 2024 年，癌症治疗领域占据最大的市场收益占有率。
  • 癌症临床试验更有可能对患者造成副作用，从而推动了对电脑模拟癌症试验的需求。
  • 由于存在多家全球公司在该市场运营，北美地区在 2024 年占据了最大的收益占有率。
  • 此外，许多 In Silico 研究正在美国进行，进一步促进了该区域​​市场的成长。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章 电脑模拟临床试验市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/补充市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 市场分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影响分析

第 4 章 In Silico 临床试验市场：产业估计与趋势分析

  • 细分仪表板
  • 全球电脑临床试验市场：产业变迁分析
  • 2018-2030年全球In Silico临床试验规模及产业趋势分析
  • 医疗设备
  • 製药

第五章电脑模拟临床试验市场：按治疗领域进行估计和趋势分析

  • 细分仪表板
  • 全球电脑模拟临床试验市场：治疗领域变异分析
  • 2018年至2030年按治疗领域分類的全球电脑临床试验规模与趋势分析
  • 肿瘤学
  • 感染疾病
  • 血液学
  • 心臟病学
  • 皮肤科
  • 神经病学
  • 糖尿病
  • 其他的

第 6 章 In Silico 临床试验市场：按阶段估计和趋势分析

  • 细分仪表板
  • 全球电脑临床试验市场：相变分析
  • 2018年至2030年全球分阶段电脑模拟临床试验规模与趋势分析
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第 7 章 In Silico 临床试验市场：区域、估计和趋势分析

  • 2024 年及 2030 年按地区分類的市场占有率分析
  • 区域市场仪表板
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 公司分类
  • 2024 年企业市场分析
  • 公司简介
    • Certara, Inc.
    • Novadiscovery Sas
    • Insilico Medicine, Inc.
    • Dassault Systemes SE
    • GNS Healthcare Inc.
    • The AnyLogic Company
    • InSilicoTrials
    • Immunetrics Inc.
    • Nuventra Pharma Sciences
    • Abzena Ltd.
Product Code: GVR-4-68039-914-9

In Silico Clinical Trials Market Growth & Trends:

The global in silico clinical trials market size is anticipated to reach USD 5.59 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 7.74% from 2025 to 2030. Traditional clinical trials require huge expenditure to conduct research. Moreover, a high number of drugs and medical devices fail in the clinical trial owing to the lack of safety and efficacy, which creates huge losses for the clinical trial sponsors. These factors promote the demand for in silico clinical trials, to understand the behavior of drugs or medical devices in humans. In silico clinical trials use simulation techniques to understand the efficacy and safety of a drug or medical device.

This reduces the chances of adverse reactions, thus, improving the safety and efficacy of research studies. The market players are making significant investments to provide new treatments to the people. For instance, in June 2021, In silico Medicine raised USD 255 million in funding to boost its R&D for drug discovery, through in silico studies. The demand for in silico clinical trials was also improved during the pandemic as there was a temporary shutdown of clinical research sites and several studies for vaccines and therapeutic agents for COVID-19 were performed through in silico research models. Such actions are likely to have a positive impact on market growth.

In Silico Clinical Trials Market Report Highlights:

  • The medical device segment dominated the market in 2024 owing to the fact that the majority of in silico trials are performed for medical devices globally
  • The phase II segment accounted for the largest market revenue share in 2024
  • The oncology therapeutic area segment accounted for the largest market revenue share in 2024
  • The cancer clinical trials have high chances of incurring adverse effects on patients, which promotes the demand for in silico trials for cancer
  • North America held the largest revenue share in 2024 due to the presence of several global players operating in the market
  • In addition, a significant number of in silico trials are performed in the U.S., which further contributes to the growth of the regional market

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis
    • 1.6.2. Bottom-up Approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. In Silico Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Cost Efficiency Associated with In silico Clinical Trials Compared to Traditional Clinical Trials
      • 3.2.1.2. Growing Trend of Eliminating/Reducing Animal Testing
      • 3.2.1.3. Increasing Technological Advancement in the In silico Clinical Trials Market
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Protein Flexibility Issues, Molecule Conformation and Promiscuity May Hinder Accurate Predictions, thus limiting its Adoption
      • 3.2.2.2. Limited Awareness in the Developing Economies
  • 3.3. Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. In Silico Clinical Trials Market: Industry Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global In Silico Clinical Trials Market: Industry Movement Analysis
  • 4.3. Global In Silico Clinical Trials Size & Trend Analysis, by Industry, 2018 to 2030 (USD Million)
  • 4.4. Medical Devices
    • 4.4.1. Medical devices market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Pharmaceutical
    • 4.5.1. Pharmaceutical market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. In Silico Clinical Trials Market: Therapeutic Area Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global In Silico Clinical Trials Market: Therapeutic Area Movement Analysis
  • 5.3. Global In Silico Clinical Trials Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
  • 5.4. Oncology
    • 5.4.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Infectious Disease
    • 5.5.1. Infectious disease market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Hematology
    • 5.6.1. Hematology market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Cardiology
    • 5.7.1. Cardiology market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.8. Dermatology
    • 5.8.1. Dermatology market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.9. Neurology
    • 5.9.1. Neurology market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.10. Diabetes
    • 5.10.1. Diabetes market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.11. Others
    • 5.11.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. In Silico Clinical Trials Market: Phase Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global In Silico Clinical Trials Market: Phase Movement Analysis
  • 6.3. Global In Silico Clinical Trials Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
  • 6.4. Phase I
    • 6.4.1. Phase I market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Phase II
    • 6.5.1. Phase II market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Phase III
    • 6.6.1. Phase III market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.7. Phase IV
    • 6.7.1. Phase IV market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. In Silico Clinical Trials Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. North America
    • 7.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Competitive scenario
      • 7.3.2.3. Regulatory framework
      • 7.3.2.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Competitive scenario
      • 7.3.3.3. Regulatory framework
      • 7.3.3.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key country dynamics
      • 7.3.4.2. Competitive scenario
      • 7.3.4.3. Regulatory framework
      • 7.3.4.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Competitive scenario
      • 7.4.4.3. Regulatory framework
      • 7.4.4.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Competitive scenario
      • 7.4.5.3. Regulatory framework
      • 7.4.5.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Competitive scenario
      • 7.4.6.3. Regulatory framework
      • 7.4.6.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Competitive scenario
      • 7.4.7.3. Regulatory framework
      • 7.4.7.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Competitive scenario
      • 7.4.8.3. Regulatory framework
      • 7.4.8.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key country dynamics
      • 7.4.9.2. Competitive scenario
      • 7.4.9.3. Regulatory framework
      • 7.4.9.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.7. Thailand
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Competitive scenario
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Competitive scenario
      • 7.7.4.3. Regulatory framework
      • 7.7.4.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Competitive scenario
      • 7.7.5.3. Regulatory framework
      • 7.7.5.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Company Market Position Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. Certara, Inc.
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Service benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. Novadiscovery Sas
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Service benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Insilico Medicine, Inc.
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Service benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Dassault Systemes SE
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Service benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. GNS Healthcare Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Service benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. The AnyLogic Company
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Service benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. InSilicoTrials
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Service benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Immunetrics Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Service benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Nuventra Pharma Sciences
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Service benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Abzena Ltd.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Service benchmarking
      • 8.3.10.4. Strategic initiatives

List of Tables

  • Table 1. List of Tables
  • Table 2. List of Secondary Sources
  • Table 3. List of Abbreviations
  • Table 4. Global In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 5. Global In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 6. Global In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 7. Global In Silico Clinical Trials, by Region, 2018 - 2030 (USD Million)
  • Table 8. North America In Silico Clinical Trials, by Country, 2018 - 2030 (USD Million)
  • Table 9. North America In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 10. North America In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 11. North America In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 12. U.S. In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 13. U.S. In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 14. U.S. In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 15. Canada In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 16. Canada In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 17. Canada In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 18. Mexico In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 19. Mexico In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 20. Mexico In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 21. Europe In Silico Clinical Trials, by Country, 2018 - 2030 (USD Million)
  • Table 22. Europe In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 23. Europe In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 24. Europe In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 25. UK In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 26. UK In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 27. UK In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 28. Germany In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 29. Germany In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 30. Germany In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 31. France In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 32. France In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 33. France In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 34. Italy In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 35. Italy In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 36. Italy In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 37. Spain In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 38. Spain In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 39. Spain In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 40. Denmark In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 41. Denmark In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 42. Denmark In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 43. Sweden In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 44. Sweden In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 45. Sweden In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 46. Norway In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 47. Norway In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 48. Norway In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 49. Asia Pacific In Silico Clinical Trials, by Country, 2018 - 2030 (USD Million)
  • Table 50. Asia Pacific In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 51. Asia Pacific In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 52. Asia Pacific In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 53. Japan In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 54. Japan In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 55. Japan In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 56. China In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 57. China In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 58. China In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 59. India In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 60. India In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 61. India In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 62. Thailand In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 63. Thailand In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 64. Thailand In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 65. South Korea In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 66. South Korea In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 67. South Korea In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 68. Australia In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 69. Australia In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 70. Australia In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 71. Latin America In Silico Clinical Trials, by Country, 2018 - 2030 (USD Million)
  • Table 72. Latin America In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 73. Latin America In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 74. Latin America In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 75. Brazil In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 76. Brazil In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 77. Brazil In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 78. Argentina In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 79. Argentina In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 80. Argentina In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 81. Middle East & Africa In Silico Clinical Trials, by Country, 2018 - 2030 (USD Million)
  • Table 82. Middle East & Africa In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 83. Middle East & Africa In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 84. Middle East & Africa In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 85. South Africa In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 86. South Africa In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 87. South Africa In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 88. Saudi Arabia In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 89. Saudi Arabia In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 90. Saudi Arabia In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 91. UAE In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 92. UAE In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 93. UAE In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 94. Kuwait In Silico Clinical Trials, by Industry, 2018 - 2030 (USD Million)
  • Table 95. Kuwait In Silico Clinical Trials, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 96. Kuwait In Silico Clinical Trials, by Phase, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 In Silico Clinical Trials Market revenue, 2018 - 2030 (USD Million)
  • Fig. 10 In Silico Clinical Trials Market snapshot
  • Fig. 11 In Silico Clinical Trials Market driver impact
  • Fig. 12 In Silico Clinical Trials Market restraint impact
  • Fig. 13 In Silico Clinical Trials Market: Industry takeaways (USD Million)
  • Fig. 14 In Silico Clinical Trials Market: Industry movement analysis
  • Fig. 15 Medical Devices market, 2018 - 2030 (USD Million)
  • Fig. 16 Pharmaceutical market, 2018 - 2030 (USD Million)
  • Fig. 17 In Silico Clinical Trials Market: Therapeutic area takeaways (USD Million)
  • Fig. 18 In Silico Clinical Trials Market: Therapeutic area movement analysis
  • Fig. 19 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 20 Infectious disease market, 2018 - 2030 (USD Million)
  • Fig. 21 Hematology market, 2018 - 2030 (USD Million)
  • Fig. 22 Cardiology market, 2018 - 2030 (USD Million)
  • Fig. 23 Dermatology market, 2018 - 2030 (USD Million)
  • Fig. 24 Neurology market, 2018 - 2030 (USD Million)
  • Fig. 25 Diabetes market, 2018 - 2030 (USD Million)
  • Fig. 26 Others market, 2018 - 2030 (USD Million)
  • Fig. 27 In Silico Clinical Trials Market: Phase takeaways (USD Million)
  • Fig. 28 In Silico Clinical Trials Market: Phase movement analysis
  • Fig. 29 Phase I market, 2018 - 2030 (USD Million)
  • Fig. 30 Phase II market, 2018 - 2030 (USD Million)
  • Fig. 31 Phase III market, 2018 - 2030 (USD Million)
  • Fig. 32 Phase IV market, 2018 - 2030 (USD Million)
  • Fig. 33 Regional marketplace: Key takeaways
  • Fig. 34 Regional outlook, 2024 & 2030
  • Fig. 35 North America In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 37 Canada In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 38 Mexico In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 39 Europe In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 40 UK In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 41 Germany In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 42 France In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 43 Italy In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 44 Spain companion animal Health market, 2018 - 2030 (USD Million)
  • Fig. 45 Sweden In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 46 Denmark In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 47 Norway In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 48 Asia Pacific In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 49 Japan In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 50 China In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 51 India In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 52 Thailand In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 53 South Korea In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 54 Australia In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 55 Latin America In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 56 Brazil In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 57 Argentina In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 58 Middle East & Africa In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 59 South Africa In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 60 Saudi Arabia In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 61 UAE In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 62 Kuwait In Silico Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 63 Market participant categorization